Patent ID: 11942149
Assignee: MACROGENICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC G

Claim 0:
1. A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a CD137×TA Binding Molecule; wherein:
the CD137×TA Binding Molecule comprises a CD137 binding domain capable of specific binding to an epitope of CD137; and
the CD137 binding domain comprises a first Light Chain Variable Domain that comprises a CDRL1, CDRL2 and CDRL3, and a first Heavy Chain Variable Domain that comprises a CDRH1, CDRH2 and CDRH3, and:
(A) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or

(B) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL15 (SEQ ID NO:222); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or

(C) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL14 (SEQ ID NO:221); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or

(D) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL11 (SEQ ID NO:218); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or

(E) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL10 (SEQ ID NO:217); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or

(F) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL6 (SEQ ID NO:213); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or

(G) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL4 (SEQ ID NO:211); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1B (SEQ ID NO:84); or

(H) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VII (SEQ ID NO:74); or

(I) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-4 VL (SEQ ID NO:91); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-4 VII (SEQ ID NO:90); or

(J) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-5 VL (SEQ ID NO:97); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-5 VII (SEQ ID NO:96); or

(K) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1A (SEQ ID NO:83); or

(L) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1C (SEQ ID NO:85); or

(M) (1) the first Light Chain Variable Domain CDRL1, CDRL2, and CDRL3 are the Light Chain CDRs of CD137 MAB-3 VL (SEQ ID NO:75); and
(2) the first Heavy Chain Variable Domain CDRH1, CDRH2, and CDRH3 are the Heavy Chain CDRs of CD137 MAB-3 VH1D (SEQ ID NO:86); and

the CD137×TA Binding Molecule comprises a TA binding domain capable of specific binding to an epitope of a tumor antigen (TA); and
the TA binding domain comprises a second Light Chain Variable Domain that comprises a CDRL1, CDRL2 and CDRL3, and a second Heavy Chain Variable Domain that comprises a CDRH1, CDRH2 and CDRH3; and
wherein the cancer is characterized by the expression of the TA.